Phage therapy

Bacteriophage collections for drug-resistant infections.

We develop and maintain bacteriophage collections against several bacterial targets. Profit is not part of our goals — a patient-first, non-commercial program.

Available phage collections

Staphylococcus aureus

Available now

94–98% of S. aureus, including MRSA

  • These are already purified and ready to be used.
  • We estimate that we have phages capable of treating 94-98% of S. aureus, including MRSA, isolates across the world.

Achromobacter xylosoxidans

A couple of months away

≈90–95% of Achromobacter isolates

  • Soon to be purified and ready to be used.
  • We estimate that the cocktail we are designing can treat approximately 90-95% of the Achromobacter isolates across the country.

Pseudomonas aeruginosa

Coming in 2027

85–90% of U.S. P. aeruginosa

  • We have phages capable of killing all isolates of P. aeruginosa we have found in the USA, including a large collection of MDR and XDR isolates from the CDC.
  • We are developing a phage cocktail of phages capable of treating 85-90% of P. aeruginosa isolates in the USA.

Escherichia coli

Coming in 2027

Most uropathogenic isolates

  • We are developing an E. coli phage collection mostly targeting uropathogenic E. coli.
  • The primary goal is to manage those with recurrent urinary tract infections, but it likely will have uses for hardware and device infections as well.
  • Thus far, we can already kill most uropathogenic E. coli isolates and are currently developing a cocktail.

Salmonella spp.

Coming in 2027

All isolates found to date

  • We have phages capable of killing all isolates of Salmonella spp. we have found across the globe.
  • We are developing a phage cocktail capable of treating all Salmonella isolates.

Klebsiella spp.

Coming in 2027 / 2028

Evolved phages; collection expanding

  • We developed evolved phages with significant activity against Klebsiella pneumoniae.
  • There are still many gaps in our Klebsiella phage collection.
  • We are continuing to fill in the gaps in this phage collection.

Featured — the Achromobacter program

Transmission electron micrographs of Achromobacter bacteriophages with their genome sizes, grouped by clade

The Achromobacter phage collection, imaged by transmission electron microscopy.

A phage collection aimed at the patients who need it.

We believe we may have developed the top Achromobacter phage collection in existence.
Our goal is to use this collection to help treat patients in need with Achromobacter infections.
Profit is not part of our goals. We simply want to help cure patients, improve their quality of life, or bridge them until they may make it to get lung transplants.
Our target populations are primarily persons with Cystic Fibrosis, bronchiectasis, other structural lung diseases, hardware infections, or other difficult to cure infections.
We do not plan to charge for these phages, but will accept donations to support our institution's efforts.
We have developed a cocktail that should treat 95% of Achromobacter infections in the USA, but have a collection capable of treating all Achromobacter infections.
We do not intend to distribute the cocktail for financial reasons.

Our target populations are primarily persons with cystic fibrosis, bronchiectasis and other structural lung diseases. Contact us for instructions at phages@ucsd.edu.